

58. **Rosenbaum DP, Mandeville WH, Pitruzzello M, et al.** Effects of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. *Nephrol Dial Transplant* 1997;12(5): 9611–964.
59. **Garg JP, Chasan-Taber S, Blair A, et al.** Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. *Arthritis Rheum* 2005;52(1):290–5.
60. **Floege J, Kubo Y, Floege A, et al.** The effect of cinacalcet on calcific uremic arteriopathy events in patients receiving hemodialysis: the EVOLVE trial. *Clin J Am Soc Nephrol* 2015;10(5):800–7.
61. **Kane WJ, Petty PM, Sterioff S, et al.** The uremic gangrene syndrome: improved healing in spontaneously forming wounds following subtotal parathyroidectomy. *Plast Reconstr Surg* 1996;98(4):671–8.
62. **Deree J, Martins JO, Melbostad H, et al.** Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. *Clinics (Sao Paulo)* 2008;63(3):321–8.
63. **Marques LJ, Zheng L, Poulakis N, et al.** Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. *Am J Respir Crit Care Med* 1999;159(2):508–11.
64. **Ward A, Clissold SP.** Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficiency. *Drugs* 1987;34(1):50–97.
65. **Full R, Delmore T, Carter C, et al.** Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. *N Engl J Med* 1992;306(4):189–94.
66. **Pautas E, Gouin I, Bellot O, et al.** Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. *Drug Saf* 2002;25(10):725–33.
67. **Caluwe R, Vandecasteele S, Van Vliem B, et al.** Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. *Nephrol Dial Transplant* 2014;29(7):1385–90.
68. **Bhat S, Hedge S, Bellovich K, et al.** Complete resolution of calciophylaxis after kidney transplantation. *Am J Kidney Dis* 2013;62(1): 132–4.
69. **Vanbellegem H, Terryn W, Van leuven L, et al.** A dramatic case of calciophylaxis 20 years after kidney transplantation. *Nephrol Dial Transplant* 2004;19(12):3183–5.

From the From the Department of Dermatology (HSJ, ARD), University of Texas Southwestern Medical Center, Dallas, TX; Department of Internal Medicine (ARD), University of Texas Southwestern Medical Center, Dallas, Texas.

Submitted September 3, 2015; accepted September 22, 2015.

The authors have no financial or other conflicts of interest to disclose.

Correspondence: Arturo R. Dominguez, MD, Department of Dermatology/Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390. (E-mail: Arturo.dominguez@utsouthwestern.edu).

ERRATUM

Erratum to: Free 25-Hydroxyvitamin D Concentrations in Cystic Fibrosis

The publisher regrets that the footnotes in the table were published incorrectly. The corrected footnotes should read as follows:

^aANOVA for normally distributed continuous variables, Kruskal-Wallis test for nonnormally distributed continuous variables, and Fisher's exact or χ^2 test for categorical variables, with Tukey's Studentized test, Steel-Dwass test and Bonferroni adjustment, respectively, for multiple comparisons.

^{b,c,e}For each variable, groups not connected by the same letter are significantly different.

^dGroups differ significantly overall, but pairwise comparisons were not significant after Bonferroni correction for multiple comparisons.

REFERENCE

Lee MJ, Kearns MD, Smith EM, et al. Free 25-hydroxyvitamin D concentrations in cystic fibrosis. *Am J Med Sci* 2015;350:374–9.